Alpha-radioimmunotherapy: a review of recent developments;Le point sur les avancées récentes de la radio-immunothérapie alpha

Cancer/Radiotherapie

Volumn 11, Issue 5, 2007, Pages 252-259

  Supiot, S ^a,b   Thillays, F ^a   Rio, E ^a   Mahe M A ^a   Barbet, F J ^b   Kraeber Bodere F ^b   Cherel M ^b  

^a CENTRE RENÉ GAUDUCHEAU   (France)

^b INSERM   (France)

Author keywords

Alpha radioimmunotherapy; High Linear Energy Transfer particles; Radiotherapy

Indexed keywords

ACTINIUM 225; BISMUTH 212; BISMUTH 213; TERBIUM; RADIOISOTOPE;

CANCER RADIOTHERAPY; CANCER STAGING; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; IRRADIATION; LINEAR ENERGY TRANSFER; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; RADIOIMMUNOTHERAPY; SHORT SURVEY; TUMOR VOLUME; ACUTE GRANULOCYTIC LEUKEMIA; ALPHA RADIATION; ANIMAL; BETA RADIATION; CELL CYCLE; COMPARATIVE STUDY; DISEASE MODEL; FEASIBILITY STUDY; METHODOLOGY; MOUSE; NEOPLASM; PHASE 1 CLINICAL TRIAL; RADIATION PROTECTION; RADIOBIOLOGY; REVIEW; THEORETICAL MODEL;

ALPHA PARTICLES; ANIMALS; BETA RAYS; CELL CYCLE; CLINICAL TRIALS, PHASE I; DISEASE MODELS, ANIMAL; FEASIBILITY STUDIES; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE; LINEAR ENERGY TRANSFER; MICE; MODELS, THEORETICAL; NEOPLASMS; RADIATION PROTECTION; RADIOBIOLOGY; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RADIOTHERAPY DOSAGE;

EID: 34648825031     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2007.05.001     Document Type: Short Survey

References (79)

1. Abbas Rizvi S.M., Henniker A.J., Goozee G., and Allen B.J. In vitro testing of the leukaemia monoclonal antibody WM-53 labeled with alpha and beta emitting radioisotopes. Leuk. Res. 26 (2002) 37-43
2. Adams G.P., Shaller C.C., Chappell L.L., Wu C., Horak E.M., Simmons H.H., et al. Delivery of the alpha-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl. Med. Biol. 27 (2000) 339-346
3. Alvarez R.D., Huh W.K., Khazaeli M.B., Meredith R.F., Partridge E.E., Kilgore L.C., et al. A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. Clin. Cancer Res. 8 (2002) 2806-2811
4. Axworthy D.B., Reno J.M., Hylarides M.D., Mallett R.W., Theodore L.J., Gustavson L.M., et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA 97 (2000) 1802-1807
5. Ballangrud A.M., Yang W.H., Charlton D.E., McDevitt M.R., Hamacher K.A., Panageas K.S., et al. Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer Res. 61 (2001) 2008-2014
6. Barendsen G.W., Koot C.J., Van Kersen G.R., Bewley D.K., Field S.B., and Parnell C.J. The effect of oxygen on impairment of the proliferative capacity of human cells in culture by ionizing radiations of different LET. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 10 (1966) 317-327
7. Behr T.M., Behe M., Stabin M.G., Wehrmann E., Apostolidis C., Molinet R., et al. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Cancer Res. 59 (1999) 2635-2643
8. Belkacemi Y., Tsoutsou P.G., Comet B., Kerrou K., and Lartigau E. [Assessment of tumor radiosensitivity using functional and metabolic nuclear imaging in research and clinical practice. A review]. Cancer Radiother. 10 (2006) 124-133
9. Bethge W.A., Wilbur D.S., Storb R., Hamlin D.K., Santos E.B., Brechbiel M.W., et al. Radioimmunotherapy with bismuth-213 as conditioning for nonmyeloablative allogeneic hematopoietic cell transplantation in dogs: a dose deescalation study. Transplantation 78 (2004) 352-359
10. Bloomer W.D., McLaughlin W.H., Lambrecht R.M., Atcher R.W., Mirzadeh S., Madara J.L., et al. 211At radiocolloid therapy: further observations and comparison with radiocolloids of 32P, 165Dy, and 90Y. Int. J. Radiat. Oncol. Biol. Phys. 10 (1984) 341-348
11. Brechbiel M.W., and Gansow O.A. Synthesis of C-Functionalized trans- Cyclohexyldiethylnenetriaminepenta-acetic acid for Labelling of monoclonal antibodies with the bismuth-212 alpha-particle emitter. J. Chem. Soc. Perkin Trans. 1 (1992) 1173-1178
12. Britz-Cunningham S.H., and Adelstein S.J. Molecular targeting with radionuclides: state of the science. J. Nucl. Med. 44 (2003) 1945-1961
13. Carlin S., Akabani G., and Zalutsky M.R. In vitro cytotoxicity of (211)at-astatide and (131)I-iodide to glioma tumor cells expressing the sodium/iodide symporter. J. Nucl. Med. 44 (2003) 1827-1838
14. Couturier O., Faivre-Chauvet A., Filippovich I.V., Thédrez P., Saï-Maurel C., Bardiès M., et al. Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma. Clin. Cancer Res. 5 (1999) 3165s-3170s
15. Couturier O., Supiot S., Degraef-Mougin M., Faivre-Chauvet A., Carlier T., Chatal J.F., et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. Mol. Imaging 32 (2005) 601-614
16. Dent P., Yacoub A., Fisher P.B., Hagan M.P., and Grant S. MAPK pathways in radiation responses. Oncogene 22 (2003) 5885-5896
17. Deutsch E., Kaliski A., Maggiorella L., and Bourhis J. [New strategies to interfere with radiation response: "biomodulation" of radiation therapy]. Cancer Radiother. 9 (2005) 69-76
18. Fowler J.F. Radiobiological aspects of low dose rates in radioimmunotherapy. Int. J. Radiat. Oncol. Biol. Phys. 18 (1990) 1261-1269
19. Gadbois D.M., Crissman H.A., Nastasi A., Habbersett R., Wang S.K., Chen D., et al. Alterations in the progression of cells through the cell cycle after exposure to alpha particles or gamma rays. Radiat. Res. 146 (1996) 414-424
20. Goodhead D.T. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int. J. Radiat. Biol. 65 (1994) 7-17
21. Hall E.J. Radiobiology for the radiologist (1994), Lippincott, Philadelphia 153-164
22. Hartmann F., Horak E.M., Garmestani K., Wu C., Brechbiel M.W., Kozak R.W., et al. Radioimmunotherapy of nude mice bearing a human interleukin 2 receptor alpha-expressing lymphoma utilizing the alpha-emitting radionuclide- conjugated monoclonal antibody 212Bi-anti-Tac. Cancer Res. 54 (1994) 4362-4370
23. Hennequin C., Giocanti N., and Favaudon V. Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res. 56 (1996) 1842-1850
24. Humm J.L. A microdosimetric model of astatine-211 labeled antibodies for radioimmunotherapy. Int. J. Radiat. Oncol. Biol. Phys. 13 (1987) 1767-1773
25. Humm J.L., Roeske J.C., Fisher D.R., and Chen G.T. Microdosimetric concepts in radioimmunotherapy. Med. Phys. 20 (1993) 535-541
26. Huneke R.B., Pippin C.G., Squire R.A., Brechbiel M.W., Gansow O.A., and Strand M. Effective alpha-particle-mediated radioimmunotherapy of murine leukemia. Cancer Res. 52 (1992) 5818-5820
27. Iyer R., and Lehnert B.E. Effects of ionizing radiation in targeted and nontargeted cells. Arch. Biochem. Biophys. 376 (2000) 14-25
28. Jenner T.J., deLara C.M., O'Neill P., and Stevens D.L. Induction and rejoining of DNA double-strand breaks in V79-4 mammalian cells following gamma- and alpha-irradiation. Int. J. Radiat. Biol. 64 (1993) 265-273
29. Jurcic J.G., Larson S.M., Sgouros G., McDevitt M.R., Finn R.D., Divgi C.R., et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100 (2002) 1233-1239
30. Kal H.B., Barendsen G.W., Hauwe R.B., and Roelse H. Increased radiosensitivity of rat rhabdomyosarcoma cells induced by protracted irradiation. Radiat. Res. 63 (1975) 521-530
31. Kaminski M.S., Tuck M., Estes J., Kolstad A., Ross C.W., Zasadny K., et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N. Engl. J. Med. 352 (2005) 441-449
32. Kaminski M.S., Zasadny K.R., Francis I.R., Milik A.W., Ross C.W., Moon S.D., et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N. Engl. J. Med. 329 (1993) 459-465
33. Kampf G. Induction of DNA double-strand breaks by ionizing radiation of different quality and their relevance for cell inactivation. Radiobiol. Radiother. (Berl.) 29 (1988) 631-658
34. Kennel S.J., Stabin M., Roeske J.C., Foote L.J., Lankford P.K., Terzaghi-Howe M., et al. Radiotoxicity of bismuth-213 bound to membranes of monolayer and spheroid cultures of tumor cells. Radiat. Res. 151 (1999) 244-256
35. Knox S.J., Sutherland W., and Goris M.L. Correlation of tumor sensitivity to low-dose-rate irradiation with G2/M-phase block and other radiobiological parameters. Radiat. Res. 135 (1993) 24-31
36. Kozak R.W., Atcher R.W., Gansow O.A., Friedman A.M., Hines J.J., and Waldmann T.A. Bismuth-212-labeled anti-Tac monoclonal antibody: alpha-particle-emitting radionuclides as modalities for radioimmunotherapy. Proc. Natl. Acad. Sci. USA 83 (1986) 474-478
37. Kraeber-Bodere F., Bardet S., Hoefnagel C.A., Vieira M.R., Vuillez J.P., Murat A., et al. Radioimmunotherapy in medullary thyroid cancer using bispecific antibody and iodine 131-labeled bivalent hapten: preliminary results of a phase I/II clinical trial. Clin. Cancer Res. 5 (1999) 3190s-3198s
38. Kraeber-Bodere F., Faibre-Chauvet A., Sai-Maurel C., Gautherot E., Fiche M., Campion L., et al. Bispecific antibody and bivalent hapten radioimmunotherapy in CEA-producing medullary thyroid cancer xenograft. J. Nucl. Med. 40 (1999) 198-204
39. Kraeber-Bodere F., Faivre-Chauvet A., Sai-Maurel C., Campion L., Fiche M., Gautherot E., et al. Toxicity and efficacy of radioimmunotherapy in carcinoembryonic antigen-producing medullary thyroid cancer xenograft: comparison of iodine 131-labeled F(ab')2 and pretargeted bivalent hapten and evaluation of repeated injections. Clin. Cancer Res. 5 (1999) 3183s-3189s
40. Langmuir V.K., and Mendonca H.L. The combined use of 131I-labeled antibody and the hypoxic cytotoxin SR 4233 in vitro and in vivo. Radiat. Res. 132 (1992) 351-358
41. Lewanski C.R., and Gullick W.J. Radiotherapy and cellular signalling. Lancet Oncol. 2 (2001) 366-370
42. Liebmann J., Cook J.A., Fisher J., Teague D., and Mitchell J.B. In vitro studies of Taxol as a radiation sensitizer in human tumor cells. J. Natl. Cancer Inst. 86 (1994) 441-446
43. Ling C.C., Spiro I.J., Mitchell J., and Stickler R. The variation of OER with dose rate. Int. J. Radiat. Oncol. Biol. Phys. 11 (1985) 1367-1373
44. Macklis R.M., Kinsey B.M., Kassis A.I., Ferrara J.L., Atcher R.W., Hines J.J., et al. Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science 240 (1988) 1024-1026
45. Macklis R.M., Beresford B.A., Palayoor S., Sweeney S., and Humm J.L. Cell cycle alterations, apoptosis, and response to low-dose-rate radioimmunotherapy in lymphoma cells. Int. J. Radiat. Oncol. Biol. Phys. 27 (1993) 643-650
46. Mahe M.A., Fumoleau P., Fabbro M., Guastalla J.P., Faurous P., Chauvot P., et al. A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. Clin. Cancer Res. 5 (1999) 3249s-3253s
47. McDevitt M.R., Sgouros G., Finn R.D., et al. Radioimmunotherapy with alpha-emitting nuclides. Eur. J. Nucl. Med. 25 (1998) 1341-1351
48. Miederer M., Seidl C., Beyer G.J., Charlton D.E., Vranjes-Duric S., Comor J.J., et al. Comparison of the radiotoxicity of two alpha-particle-emitting immunoconjugates, terbium-149 and bismuth-213, directed against a tumor-specific, exon 9 deleted (d9) E-cadherin adhesion protein. Radiat. Res. 159 (2003) 612-620
49. Mitchell J.B., Bedford J.S., and Bailey S.M. Dose-rate effects in mammalian cells in culture III. Comparison of cell killing and cell proliferation during continuous irradiation for six different cell lines. Radiat. Res. 79 (1979) 537-551
50. Mulford D.A., Scheinberg D.A., and Jurcic J.G. The promise of targeted {alpha}-particle therapy. J. Nucl. Med. 46 (2005) 199S-204S
51. Munro T.R. The relative radiosensitivity of the nucleus and cytoplasm of Chinese hamster fibroblasts. Radiat. Res. 42 (1970) 451-470
52. Nikjoo H., Uehara S., Wilson W.E., Hoshi M., and Goodhead D.T. Track structure in radiation biology: theory and applications. Int. J. Radiat. Biol. 73 (1998) 355-364
53. Ning S., and Knox S.J. G2/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation. Radiat. Res. 151 (1999) 659-669
54. Pedley R.B., Begent R.H., Boden J.A., Boden R., Adam T., and Bagshawe K.D. The effect of radiosensitizers on radio-immunotherapy, using 131I-labelled anti-CEA antibodies in a human colonic xenograft model. Int. J. Cancer 47 (1991) 597-602
55. Pouget J.P., and Mather S.J. General aspects of the cellular response to low- and high-LET radiation. Eur. J. Nucl. Med. 28 (2001) 541-561
56. Press O.W., Eary J.F., Appelbaum F.R., Martin P.J., Badger C.C., Nelp W.B., et al. Radiolabeled-antibody therapy of Bcell lymphoma with autologous bone marrow support. N. Engl. J. Med. 329 (1993) 1219-1224
57. Radford I.R. Evidence for a general relationship between the induced level of DNA double-strand breakage and cell-killing after X-irradiation of mammalian cells. Int. J. Radiat. Biol. Relat. Stud. Phys. Chem. Med. 49 (1986) 611-620
58. Regaud C., and Lacassagne A. La radiosensibilité cellulaire étudiée dans l'ensemble de ses manifestations. Radiophysiol. Radiother. 1 (1927) 95-116
59. Sandmaier B.M., Bethge W.A., Wilbur D.S., Hamlin D.K., Santos E.B., Brechbiel M.W., et al. Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts. Blood 100 (2002) 318-326
60. Schiff P.B., and Horwitz S.B. Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA 77 (1980) 1561-1565
61. Schmidt-Ullrich R.K., Mikkelsen R.B., Dent P., Todd D.G., Valerie K., Kavanagh B.D., et al. Radiation-induced proliferation of the human A431 squamous carcinoma cells is dependent on EGFR tyrosine phosphorylation. Oncogene 15 (1997) 1191-1197
62. Sharkey R.M., and Goldenberg D.M. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J. Nucl. Med. 46 (2005) 115S-127S
63. Simonson R.B., Ultee M.E., Hauler J.A., and Alvarez V.L. Radioimmunotherapy of peritoneal human colon cancer xenografts with site-specifically modified 212Bi-labeled antibody. Cancer Res. 50 (1990) 985s-988s
64. Sinclair W.K., and Morton R.A. X-ray sensitivity during the cell generation cycle of cultured Chinese hamster cells. Radiat. Res. 29 (1966) 450-474
65. Spiro I.J., Ling C.C., Stickler R., and Gaskill J. Oxygen radiosensitisation at low dose rate. Br. J. Radiol. 58 (1985) 357-363
66. Steel G.G., Deacon J.M., Duchesne G.M., Horwich A., Kelland L.R., and Peacock J.H. The dose-rate effect in human tumour cells. Radiother. Oncol. 9 (1987) 299-310
67. Stinchcomb T.G., and Roeske J.C. Analytic microdosimetry for radioimmunotherapeutic alpha emitters. Med. Phys. 19 (1992) 1385-1393
68. Supiot S., Faivre-Chauvet A., Couturier O., Heymann M.F., Robillard N., Kraeber-Bodéré F., et al. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer 94 (2002) 1202-1209
69. Supiot S., Gouard S., Charrier J., Apostolidis C., Chatal J.F., Barbet J., et al. Mechanisms of cell sensitization to alpha radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin. Cancer Res. 11 (2005) 7047s-7052s
70. Tishler R.B., Geard C.R., Hall E.J., and Schiff P.B. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res. 52 (1992) 3495-3497
71. van Oostrum I.E., Erkens-Schulze S., Petterson M., Wils I.S., and Rutgers D.H. The relationship between radiosensitivity and cell kinetic effects after low- and high-dose-rate irradiation in five human tumors in nude mice. Radiat. Res. 122 (1990) 252-261
72. Ward J.F. Some biochemical consequences of the spatial distribution of ionizing radiation-produced free radicals. Radiat. Res. 86 (1981) 185-195
73. Wilder R.B., McGann J.K., Sutherland W.R., Waller E.K., Minchinton A.I., Goris M.L., et al. The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts. Int. J. Radiat. Oncol. Biol. Phys. 28 (1994) 119-126
74. Withers H.R., Mason K., Reid B.O., Dubravsky N., Barkley H.T., Brown B.W., et al. Response of mouse intestine to neutrons and gamma rays in relation to dose fractionation and division cycle. Cancer 34 (1974) 39-47
75. Woloschak G.E., and Chang-Liu C.M. Differential modulation of specific gene expression following high- and low-LET radiations. Radiat. Res. 124 (1990) 183-187
76. Yao Z., Garmestani K., Wong K.J., Park L.S., Dadachova E., Yordanov A., et al. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J. Nucl. Med. 42 (2001) 1538-1544
77. Zalutsky M.R., Cokgor I., Akabani G., et al. Phase I trial of alpha-particle-emitting astatine-211 labeled chimeric antitenascin antibody in recurrent malignant glioma patients. Proc. Am. Assoc. Cancer Res. 41 (2000) 54
78. Zhang M., Yao Z., Garmestani K., Axworthy D.B., Zhang Z., Mallett R.W., et al. Pretargeting radioimmunotherapy of a murine model of adult T-cell leukemia with the alpha-emitting radionuclide, bismuth 213. Blood 100 (2002) 208-216
79. Zhang M., Zhang Z., Garmestani K., Schultz J., Axworthy D.B., Goldman C.K., et al. Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc. Natl. Acad. Sci. USA 100 (2003) 1891-1895